Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Liver disease marker, method and apparatus for measuring same, and test method for pharmaceutical preparation

A technology for markers and pharmaceuticals, which is applied in the field of liver disease markers, its determination, equipment and pharmaceutical inspection, and can solve problems such as glutathione consumption

Active Publication Date: 2013-03-13
KEIO UNIV
View PDF6 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, if figure 1 As in the oxidation state shown in (B), glutathione is consumed by detoxification if there are electrophilic substances and active oxygen species

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Liver disease marker, method and apparatus for measuring same, and test method for pharmaceutical preparation
  • Liver disease marker, method and apparatus for measuring same, and test method for pharmaceutical preparation
  • Liver disease marker, method and apparatus for measuring same, and test method for pharmaceutical preparation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0084] Hereinafter, embodiments of the present invention will be described in detail.

[0085] As described above, it is known that various liver injuries such as hepatitis, liver cirrhosis, and liver cancer are closely related to oxidative stress. Therefore, 53 healthy people (C), 10 drug-induced liver injury (DI), 9 asymptomatic hepatitis B carriers (AHB), 7 chronic hepatitis B (CHB), and 10 HCV positive ALT persistent Normal subjects (CNALT), 24 patients with chronic hepatitis C (CHC), 10 patients with liver cirrhosis (CIR), 19 patients with liver cancer (HCC), 11 patients with nonalcoholic steatohepatitis (NASH), 9 patients with simple fatty Liver (SS) sera were assayed for retinoic acid concentrations using capillary electrophoresis-time-of-flight mass spectrometry (CE-TOFMS). However, other substances were found to increase in predominance in each hepatitis patient, and they were all identified as γ-Glu-X peptides (Note: X indicates amino acid and amine).

[0086] 1. E...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
lengthaaaaaaaaaa
Login to View More

Abstract

Disclosed is a method for promptly identifying a liver disease. A normal person (C) or a liver disease such as drug-induced liver injury (DI), asymptomatic hepatitis B carrier (AHB), chronic hepatitis B (CHB), hepatitis C with persistently normal ALT (CNALT), chronic hepatitis C (CHC), cirrhosis type C (CIR), hepatocellular carcinoma (HCC), simple steatosis (SS), or non-alcoholic steatohepatitis (NASH) is identified by measuring the concentration of a gamma-Glu-X (wherein X represents an amino acid or an amine) peptide or the level of AST or ALT in blood and carrying out, for example, a multiple logistic regression (MLR) based on the measured value.

Description

technical field [0001] The present invention relates to liver disease markers, their assay methods, devices, and pharmaceutical testing methods, and in particular, to liver disease markers that can be screened by distinguishing various liver disease patients from healthy individuals, their assay methods, devices, and the use of The test method of the medicine of this liver disease marker. Background technique [0002] Liver diseases include various liver diseases such as drug-induced liver injury, hepatitis B, hepatitis C, cirrhosis, and liver cancer. In addition, there are asymptomatic carriers of B virus and C virus. In particular, 70% of hepatitis C virus (hepatitis type Cvirus: HCV) infected patients gradually lose normal liver cells due to chronic liver inflammation (chronic hepatitis), liver fibrosis, and then develop into cirrhosis, and even develop into liver cancer. According to reports, 10-15% of patients with chronic hepatitis C and 80% of patients with liver ci...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): G01N33/68G01N33/15G01N33/50
CPCG01N2800/7009G01N33/576G01N2800/085G01N33/5767
Inventor 曽我朋义杉本昌弘末松诚斋藤贵史河田纯男
Owner KEIO UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com